Palatin Technologies reported no revenue for the fiscal third quarter ended March 31, 2025, following the sale of Vyleesi rights. The company significantly reduced its net loss and operating expenses compared to the same period last year, primarily due to decreased spending on MCR programs. They ended the quarter with $2.5 million in cash and cash equivalents and are exploring funding options.

Palatin Technologies reported a net loss of $7.8 million for the quarter ended September 30, 2024, compared to a net loss of $5.2 million for the same period in 2023. The company had no product sales due to the sale of Vyleesi's worldwide rights. The company's cash and cash equivalents were $2.4 million as of September 30, 2024.

Palatin Technologies reported a net loss of $8.6 million for the fourth quarter ended June 30, 2024, compared to a net loss of $9.8 million for the same period in 2023. The decrease in net loss was mainly due to the decrease in Vyleesi operating expenses, offset by the elimination of net product revenue of Vyleesi and the recognition of the change in fair value of warrant liabilities for the quarter ended June 30, 2023.

Palatin Technologies reported a net loss of $8.4 million, or $(0.53) per common share, for the quarter ended March 31, 2024. They had no product revenue due to the sale of Vyleesi. Cash, cash equivalents, and marketable securities totaled $10.0 million as of March 31, 2024.

Palatin Technologies reported a net loss of $7.8 million, or $(0.56) per basic and diluted common share, for the quarter ended December 31, 2023. Vyleesi gross product sales were $4.3 million, with net product revenue of $2.0 million. The company's focus is now solely on advancing its melanocortin-based development and clinical pipeline.

Palatin Technologies reported an 11% increase in gross product revenue and a 20% increase in net product revenue compared to the prior quarter. Vyleesi's quarterly net product revenue continues to exceed Vyleesi quarterly operating expenses.

Palatin Technologies reported its Q4 2023 financial results, with Vyleesi's net product revenue increasing by 47% and prescriptions dispensed increasing by 16% over the prior quarter. The Phase 3 PL9643 clinical study is fully enrolled, with interim analysis showing statistically significant positive effects on multiple endpoints.

Palatin Technologies announced positive Phase 3 clinical study data for PL9643 in dry eye disease and reported Vyleesi's fifth consecutive quarter of double-digit growth in net product revenue. The company's net loss decreased compared to the same quarter last year, driven by increased Vyleesi revenue.

Palatin Technologies reported an increase in Vyleesi's net product sales by 18% and prescriptions dispensed by 12% over the prior quarter. Net product revenue for the quarter ended December 31, 2022, reached approximately $1 million, exceeding Vyleesi operating expenses.

Palatin Technologies reported a net loss of $8.3 million for the quarter ended September 30, 2022. Net product revenue increased 13% over the prior quarter and 445% over the comparable quarter in 2021. Cash and cash equivalents were $21.2 million as of September 30, 2022.

Palatin Technologies reported a net loss of $12.8 million for the quarter ended June 30, 2022. Vyleesi gross product sales were $2.3 million, with net product revenue of $770,738. The company's cash and cash equivalents totaled $29.9 million as of June 30, 2022.

Palatin Technologies reported financial results for the third quarter of fiscal year 2022. Net product revenue increased 144% compared to the same quarter in 2021, while the company experienced a net loss of $7.6 million. As of March 31, 2022, Palatin's cash and cash equivalents were approximately $37.7 million.

Palatin Technologies reported a net loss of $8.7 million for the quarter ended December 31, 2021, with total revenues including $72,140 in net product revenue from Vyleesi and $250,000 in license and contract revenue. The company's cash and cash equivalents stood at $47.3 million as of December 31, 2021, expected to fund operations through at least March 2023.

Palatin Technologies reported its Q1 2022 financial results, with net revenue increasing by 98% and net revenue per prescription up by 45% compared to the previous quarter. The company is advancing its melanocortin agonist programs, including a Phase 3 pivotal study of PL9643 for dry eye disease and a Phase 2 clinical trial of PL8177 for ulcerative colitis.

Palatin Technologies reported a net loss of $13.9 million for the quarter ended June 30, 2021. The company's cash and cash equivalents were $60.1 million as of June 30, 2021, providing a cash runway through calendar year 2022.

Palatin Technologies reported a net loss of $5.7 million, or $(0.02) per share, for the third quarter ended March 31, 2021. Total net revenues, consisting of net product revenues of Vyleesi, were $88,741. The company had $68.6 million in cash and cash equivalents as of March 31, 2021.

Palatin Technologies reported a net loss of $10.0 million, or $(0.04) per share, for the quarter ended December 31, 2020. The company had $72.2 million in cash and cash equivalents as of December 31, 2020. Vyleesi gross sales for the quarter amounted to $943,950, with product revenue of $(163,971), net of allowances and accruals.

Palatin Technologies reported a net loss of $3.9 million for the quarter ended September 30, 2020. The company regained North American rights to Vyleesi® and had $86.6 million in cash and cash equivalents as of September 30, 2020.

Palatin Technologies reported a net loss of $7.3 million for the fourth quarter ended June 30, 2020, compared to a net income of $52.2 million for the comparable quarter of 2019. The decrease is primarily due to the recognition of license and contract revenue from the AMAG license agreement in the previous year. As of June 30, 2020, the company had $82.9 million in cash and cash equivalents.

Palatin Technologies reported a net loss of $5.4 million for the third quarter of fiscal year 2020, compared to a net loss of $5.7 million for the same period in 2019. The company's cash and cash equivalents were $88.9 million as of March 31, 2020. They are continuing to advance their clinical programs.

Palatin Technologies reported a net loss of $5.2 million for the quarter ended December 31, 2019. The company's cash position was enhanced to $92 million as of December 31, 2019, and they are advancing their pipeline programs with two Phase 2 clinical studies starting in the first half of calendar year 2020.